HLA-DRB1* 15 allele influences the later course of relapsing remitting multiple sclerosis

Genes and Immunity

Volumn 9, Issue 6, 2008, Pages 570-574

  Cournu Rebeix, I ^a,b,c   Genin E ^a,d   Leray, E ^e   Babron, M C ^a,d   Cohen, J ^a,b   Gout, C ^a,b   Alizadeh, M ^f   Perdry, H ^a,d   Semana, G ^f   Brassat, D ^f   Clerget Darpoux, F ^a   Yaouanq, J ^a,d   Edan, G ^e   Rosenheim, M ^g   Fontaine, B ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE RENNES 1   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; HLA DRB1*15 ANTIGEN; HLA-DRB1*15 ANTIGEN;

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DNA MODIFICATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECURRENT DISEASE; RELAPSE; REMISSION; RISK FACTOR; SCORING SYSTEM; ADOLESCENT; CHILD; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; CHILD; FEMALE; HLA-DR ANTIGENS; HUMANS; MALE; MULTIPLE SCLEROSIS;

EID: 51249089462     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2008.52     Document Type: Article

References (25)

1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: Genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61-76.
2. Compston DA, Kellar Wood H, Robertson N, Sawcer S, Wood NW. Genes and susceptibility to multiple sclerosis. Acta Neurol Scand Suppl 1995; 161: 43-51.
3. Ebers GC, Dyment DA. Genetics of multiple sclerosis. Semin Neurol. 1998; 18: 295-299.
4. Jersild C, Fog T. Histocompatibility (HL-A) antigens associated with multiple sclerosis. Acta Neurol Scand Suppl 1972; 51: 377.
5. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083-1001.
6. Lundmark F, Duvefelt K, Iacobaeus E, Kockum. I, Wallstrom E, Khademi M et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108-1113.
7. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
8. Ramagopalan SV, Anderson C, Sadovnick AD, Ebers GC. Genomewide study of multiple sclerosis. N Engl J Med 2007; 357: 2199-2200; author reply 2200-2201.
9. Weber F, Fontaine B, Cournu-Rebeix I, Kroner A, Knop M, Lutz S et al IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008; 9 259-263.
10. Olsson T, Jagodic M, Piehl F, Wallstrom E. Genetics of autoimmune neuroinflammation. Curr Opin Immunol 2006; 18: 643-649.
11. Lublin FD, Reingold SC, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996; 46: 907-911.
12. Weinshenker BG. The natural history of multiple sclerosis: Update 1998. Semin Neurol 1998; 18: 301-307.
13. Stankoff B, Mrejen S, Tourbah A, Fontaine B, Lyon-Caen O, Lubetzki C et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology 2007; 68: 779-781.
14. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 2006; 129 (Part 3): 606-616.
15. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: New insights. Curr Opin Neurol 2006; 19: 248-254.
16. Hensiek AE, Seaman SR, Barcellos LF, Oturai A, Eraksoi M, Cocco E et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007; 68: 376-383.
17. DeLuca GC, Ramagopalan SV, Herrera BM, Dyment DA, Lincoln MR, Montpetit A et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA 2007; 104: 20896-20901.
18. Brassat D, Azais-Vuillemin C, Yaouanq J, Semana G, Reboul J, Cournu I, et al., French Multiple Sclerosis Genetics Group. Familial factors influence disability in MS multiplex families. Neurology 1999; 52: 1632-1636.
19. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
21. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology 2005; 64 1144-1151.
22. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003; 72: 710-716.
23. Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 200615; 15: 2813-2824.
24. Umbach DM, Weinberg CR. The use of case-parent triads to study joint effects of genotype and exposure. Am J Hum Genet 2000; 66: 251-261.
25. Venken K, Hellings N, Hensen K, Rummens; JL, Medaer R, D'Hooghe MB et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83: 1432-1446.